Title |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies
|
---|---|
Published in |
Targeted Oncology, January 2015
|
DOI | 10.1007/s11523-014-0331-z |
Pubmed ID | |
Authors |
Lorinda L. Covell, Apar Kishor Ganti |
Abstract |
Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 4 | 20% |
Professor > Associate Professor | 3 | 15% |
Other | 2 | 10% |
Researcher | 2 | 10% |
Student > Bachelor | 2 | 10% |
Other | 2 | 10% |
Unknown | 5 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 25% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 5% |
Agricultural and Biological Sciences | 1 | 5% |
Nursing and Health Professions | 1 | 5% |
Other | 2 | 10% |
Unknown | 9 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2016.
All research outputs
#20,334,427
of 22,879,161 outputs
Outputs from Targeted Oncology
#510
of 551 outputs
Outputs of similar age
#297,040
of 353,311 outputs
Outputs of similar age from Targeted Oncology
#6
of 7 outputs
Altmetric has tracked 22,879,161 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 551 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,311 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.